Literature DB >> 24297447

Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer.

Johji Hara1, Hiroshi Miyata1, Makoto Yamasaki1, Keijiro Sugimura1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Kiyokazu Nakajima1, Shuji Takiguchi1, Masaki Mori1, Yuichiro Doki1.   

Abstract

The relationship between the epithelial-mesenchymal transition (EMT) and resistance to anticancer treatment has attracted attention in recent years. However, to date, there is no direct clinical evidence for a link between the mesenchymal phenotype and chemoresistance in human malignancies. The expression of EMT-related markers, including E-cadherin, Snail, vimentin, ZEB1, β-catenin and N-cadherin was examined immunohistochemically in 185 tissue samples from patients with esophageal cancer (including 93 patients who received preoperative chemotherapy followed by surgery and 92 patients who underwent surgery without preoperative therapy). The relationship between the expression of the above markers and clinical outcome including prognosis and response to chemotherapy was also examined. The expression of E-cadherin, a marker of epithelial cells, was significantly lower in residual tumors than chemo-naive tumors (P=0.003). The expression of Snail (P=0.028), ZEB1 (P<0.001) and N-cadherin (P=0.001), markers of mesenchymal cells, was higher in residual tumors than in chemonaive tumors. The expression of E-cadherin correlated inversely with that of Snail (P<0.001). Reduced expression of E-cadherin and increased expression of Snail in residual tumors from patients who received chemotherapy correlated significantly with poor response to chemotherapy and short survival time. Multivariate analysis identified Snail expression as an independent prognostic factor, along with tumor depth, in patients who received preoperative chemotherapy for esophageal cancer. The results suggest transition of residual esophageal cancer cells to mesenchymal phenotype after chemotherapy and this contributes to resistance to chemotherapy and poor prognosis in patients with esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297447     DOI: 10.3892/or.2013.2876

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

Review 2.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

Review 3.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

4.  Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p.

Authors:  Jovana Despotovic; Sandra Dragicevic; Aleksandra Nikolic
Journal:  Cell Biochem Biophys       Date:  2021-04-07       Impact factor: 2.194

5.  Cultivation of Head and Neck Squamous Cell Carcinoma Cells with Wound Fluid Leads to Cisplatin Resistance via Epithelial-Mesenchymal Transition Induction.

Authors:  Till Jasper Meyer; Manuel Stöth; Helena Moratin; Pascal Ickrath; Marietta Herrmann; Norbert Kleinsasser; Rudolf Hagen; Stephan Hackenberg; Agmal Scherzad
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

6.  Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma.

Authors:  Minhua Wang; Jeannelyn S Estrella; Matthew H Katz; Michael Kim; Asif Rashid; Jeffrey E Lee; Anirban Maitra; Ignacio I Wistuba; Robert A Wolff; Gauri R Varadhachary; Huamin Wang
Journal:  Pancreas       Date:  2019 Nov/Dec       Impact factor: 3.243

7.  Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.

Authors:  Alexander Krohn; Theresa Ahrens; Arzu Yalcin; Till Plönes; Julius Wehrle; Sanaz Taromi; Stefan Wollner; Marie Follo; Thomas Brabletz; Sendurai A Mani; Rainer Claus; Björn Hackanson; Meike Burger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

8.  Prognostic significance of ZEB1 and ZEB2 in digestive cancers: a cohort-based analysis and secondary analysis.

Authors:  Huihui Chen; Wei Lu; Chongjie Huang; Kefeng Ding; Dajing Xia; Yihua Wu; Mao Cai
Journal:  Oncotarget       Date:  2017-05-09

Review 9.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

10.  The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.

Authors:  Guangyu Wang; Dandan Xu; Zicheng Zhang; Xinhui Li; Jiaqi Shi; Jie Sun; Huan-Zhong Liu; Xiaobo Li; Meng Zhou; Tongsen Zheng
Journal:  NPJ Precis Oncol       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.